z-logo
open-access-imgOpen Access
Influence of CYP2D6 genetic variation on adverse events with propafenone in the pediatric and young adult population
Author(s) -
Sunthankar Sudeep D.,
Kannankeril Prince J.,
Gaedigk Andrea,
Radbill Andrew E.,
Fish Frank A.,
Van Driest Sara L.
Publication year - 2022
Publication title -
clinical and translational science
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.303
H-Index - 44
eISSN - 1752-8062
pISSN - 1752-8054
DOI - 10.1111/cts.13296
Subject(s) - propafenone , cyp2d6 , medicine , adverse effect , population , genetic variation , variation (astronomy) , pharmacology , environmental health , cytochrome p450 , physics , astrophysics , metabolism , atrial fibrillation
Propafenone is an antiarrhythmic drug metabolized primarily by cytochrome P450 2D6 (CYP2D6). In adults, propafenone adverse events (AEs) are associated with CYP2D6 poor metabolizer status; however, pediatric data are lacking. Subjects were tested for 10 CYP2D6 allelic variants and copy number status, and activity scores assigned to each genotype. Seventy‐six individuals (median 0.3 [range 0–26] years old) were included. Propafenone AEs occurred in 29 (38%); 14 (18%) required drug discontinuation due to AE. The most common AEs were QRS ( n  = 10) and QTc ( n  = 6) prolongation. Those with AEs were older at the time of propafenone initiation (1.58 [0.13–9.92] vs. 0.20 [0.08–2.01] years old; p  = 0.042). CYP2D6 activity scores were not associated with presence of an AE (odds ratio [OR] 0.48 [0.22–1.03]; p  = 0.055) but with the total number of AE ( β 1  = −0.31 [−0.60, −0.03]; p  = 0.029), systemic AEs (OR 0.33 [0.13–0.88]; p  = 0.022), and drug discontinuation for systemic AEs (OR 0.28 [0.09–0.83]; p  = 0.017). Awareness of CYP2D6 activity score and patient age may aid in determining an individual's risk for an AE with propafenone administration.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here